Fodders
2022
Will California's opioid guidelines cave to industry pressure? By Judy Butler, Research Fellow (August 2022)
McKinsey & Company: Double Agent for Purdue and FDA By Judy Butler, Research Fellow (May 2022)
Let's lose the term "legitimate pain patient" By Judy Butler, Research Fellow (March 2022)
"It's a trap!" A doctor and a patient duped by Pharma speak out By Judy Butler, Research Fellow (February 2022)
2021
The House and the Senate Take on Opioid Marketing By Judy Butler, Research Fellow (January 2021)
Why is the AMA Promoting Opioid Use? By Judy Butler, Research Fellow (February 2021)
Opioid Marketing Tactics: The Old and the New By Judy Butler, Research Fellow (March 2021)
New and Convenient Does Not Equal Better and Safe By Judy Butler, Research Fellow (April 2021)
Another Key Player in Purdue's Opioid Marketing Strategy By Judy Butler, Research Fellow (May/June 2021)
What Does a "Human Rights" Frame for Pain Advocacy Look Like? By Judy Butler, Research Fellow (July 2021)
Manufacturing Doubt and Evading Responsibility By Judy Butler, Research Fellow (September 2021)
The FDA Should Mandate Industry-free CME by Judy Butler, Research Fellow (October 2021)
Sales of Some Opioids Lift Sales of All Opioids by Judy Butler, Research Fellow (November 2021)
2020
Story vs. Anti-Story in Opioid Marketing By Judy Butler, Research Fellow (January 2020)
The Trouble with Tramadol By Judy Butler, Research Fellow (February 2020)
We Know About Opioids, but Where Else Are Pharma Payments Going? By Judy Butler, Research Fellow (March 2020)
Fact or Fiction? How Opioid Misinformation Continues Online By Judy Butler, Research Fellow (April 2020)
Triplicate States and Opioid Prescribing By Judy Butler, Research Fellow (May 2020)
Asking About Pain Tolerance Could Lead to Fewer Opioid Prescriptions By Judy Butler, Research Fellow (June 2020)
Will the CDC Opioid Guideline Update be Informed by Scientific Evidence or Narrative? By Judy Butler, Research Fellow (July 2020)
Yet Another Industry-Friendly Platform for Opioid Promotion By Judy Butler, Research Fellow (August 2020)
The UK's Take on the Treatment of Chronic Primary Pain By Judy Butler, Research Fellow (September 2020)
Industry's Influence on Pain Patients' Advocacy By Judy Butler, Research Fellow (October 2020)
Purdue's Most Successful Strategy No One Is Talking About By Judy Butler, Research Fellow (November 2020)
McKinsey Proposed What to Purdue? By Judy Butler, Research Fellow (December 2020)
2019
What Really Helps Chronic Pain Patients By Judy Butler, Research Fellow (February 2019)
Industry's Voice, Pain Patient's Face By Judy Butler, Research Fellow (March 2019)
Who's Really Advocating for Pain Patients By Judy Butler, Research Fellow (April 2019)
Preventing a new generation of opioid “legacy patients" By Judy Butler, Research Fellow (May 2019)
Highlights from the Johnson & Johnson Opioids Verdict By Judy Butler, Research Fellow (August/September 2019)
Disinfecting Pharma with Sunshine: The Case for Bringing Documents to Light By Judy Butler, Research Fellow (October 2019)
When Sunshine Doesn't Cast Enough Light By Judy Butler, Research Fellow (November 2019)
In Opioid Cases, Look to Tobacco Litigation for Guidance By Adriane Fugh-Berman and Robert Weissman (December 2019)
2018
Purdue's Latest PR Move By Judy Butler, Research Fellow (April 2018)
Pharma and the NIH: Innocence By Association? By Judy Butler, Research Fellow and Dr. Adriane Fugh-Berman (May 2018)
Subsys Sales, from Salacious to Scammy By Judy Butler, Research Fellow (July 2018)
A Million Ways to Market A Pill By Judy Butler, Research Fellow (August 2018)
Greater Decline in Opioid Prescribing After CDC Guidelines Released By Judy Butler, Research Fellow (October 2018)
Make Punishment Personal By Judy Butler, Research Fellow (November 2018)
An opioid treatment for depression nixed by FDA advisory committee By Ben Goodwin (December 2018)